No significant differences in PFS or OS were observed according to the cytomorphologic subtype of DLBCL, individual marker expression (i.e., CD10, BCL6, or MUM1/IRF4), COO subtype, or Ki-67 proliferation index (all p-values >0.1). This evidence concerns the gene IRF4 and diffuse large B-cell lymphoma.